Metformin in the treatment of pancreatic cancer
Upcoming SlideShare
Loading in...5
×

Like this? Share it with your network

Share
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
296
On Slideshare
296
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Editoriale Page 1 of 1 Metformin in the treatment of pancreatic cancer Patients with pancreatic cancer often have a high prevalence (80%) of concurrent diabetes or impaired glucose tolerance, which are characterized by peripheral insulin resistance. Accumulating epidemiological and experimental evidence suggest metformin, the most commonly used antidiabetic drug, as an antitumor agent. In our retrospective study of 302 diabetic patients with pancreatic cancer, we observed that metformin users had 4 months longer overall survival time, 32% reduced risk of death, and about 2-fold higher 2-year survival rate than the nonmetformin group. These observations add supporting evidence for the antitumor activity of metformin. Findings from this retrospective investigation should prompt future research to test the hypothesis that metformin can be used as a supplemental therapy in the treatment of pancreatic cancer. Bibliographic Reference: Sadeghi N et al.: "Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer", Clin Cancer Res. 2012 Mar 31. [Epub ahead of print] Donghui Li Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texasfile://C:Documents and SettingsutenteDesktopEdit_Li.htm 08/05/2012